Suscribirse

Financial Reinforcers for Improving Medication Adherence: Findings from a Meta-analysis - 30/08/12

Doi : 10.1016/j.amjmed.2012.01.003 
Nancy M. Petry, PhD , Carla J. Rash, PhD, Shannon Byrne, PhD, Shehryar Ashraf, MD, William B. White, MD
Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington 

Requests for reprints should be addressed to Nancy M. Petry, PhD, Calhoun Cardiology Center, MC-3944, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3944

Abstract

Background

Increasingly, financial reinforcement interventions based on behavioral economic principles are being applied in health care settings, and this study examined the use of financial reinforcers for enhancing adherence to medications.

Methods

Electronic databases and bibliographies of relevant references were searched, and a meta-analysis of identified trials was conducted. The variability in effect size and the impact of potential moderators (study design, duration of intervention, magnitude of reinforcement, and frequency of reinforcement) on effect size were examined.

Results

Fifteen randomized studies and 6 nonrandomized studies examined the efficacy of financial reinforcement interventions for medication adherence. Financial reinforcers were applied for adherence to medications for tuberculosis, substance abuse, human immunodeficiency virus, hepatitis, schizophrenia, and stroke prevention. Reinforcement interventions significantly improved adherence relative to control conditions with an overall effect size of 0.77 (95% confidence interval, 0.70-0.84; P<.001). Nonrandomized studies had a larger average effect size than randomized studies, but the effect size of randomized studies remained significant at 0.44 (95% confidence interval, 0.35-0.53; P<.001). Interventions that were longer in duration, provided an average reinforcement of $50 or more per week, and reinforced patients at least weekly resulted in larger effect sizes than those that were shorter, provided lower reinforcers, and reinforced patients less frequently.

Conclusion

These results demonstrate the efficacy of medication adherence interventions and underscore principles that should be considered in designing future adherence interventions. Financial reinforcement interventions hold potential for improving medication adherence and may lead to benefits for both patients and society.

El texto completo de este artículo está disponible en PDF.

Keywords : Financial, Medication adherence, Meta-analysis, Reinforcement


Esquema


 Funding: The research and preparation of this report were supported by National Institutes of Health Grants P30-DA023918, R01-DA024667, R01-DA027615, R01-DA022739, R01-DA13444, R01-DA018883, R01-DA016855, R01-DA14618, P50-DA09241, P60-AA03510, and T32-AA07290.
 Conflict of Interest: None.
 Authorship: All authors had access to the data and played a role in writing this manuscript.


© 2012  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 125 - N° 9

P. 888-896 - septembre 2012 Regresar al número
Artículo precedente Artículo precedente
  • Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients
  • Sayed H. Naderi, Jonathan P. Bestwick, David S. Wald
| Artículo siguiente Artículo siguiente
  • Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes
  • Renato D. Lopes, Li Li, Christopher B. Granger, Tracy Y. Wang, JoAnne M. Foody, Marjorie Funk, Eric D. Peterson, Karen P. Alexander

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.